 Shares in Tiziana Life Sciences PLC raced 20 higher in the opening minutes of trading on Wall Street after the group inked an exclusive licensing agreement with Precision BioSciences NASDAQ:DTIL. The tie-up takes it into the exciting arena of CAR-T therapy with the pair looking to use Tizianas foralumab monoclonal antibody mAb to enhance the next generation of cancer treatments. 